BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 8911991)

  • 1. Role of sulfonylureas in non-insulin-dependent diabetes mellitus: Part II--"The cons".
    Heine RJ
    Horm Metab Res; 1996 Sep; 28(9):522-6. PubMed ID: 8911991
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral hypoglycemic agents in type II diabetes mellitus.
    Lubbos H; Miller JL; Rose LI
    Am Fam Physician; 1995 Nov; 52(7):2075-8. PubMed ID: 7484707
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Insulin as a first-line therapy in type 2 diabetes: should the use of sulfonylureas be halted?
    Standl E; Schnell O
    Diabetes Care; 2008 Feb; 31 Suppl 2():S136-9. PubMed ID: 18227474
    [No Abstract]   [Full Text] [Related]  

  • 4. Exploring the role of sulfonylureas in the treatment of non-insulin-dependent diabetes mellitus.
    Graham JP; Stam D
    Pharm Pract Manag Q; 1997 Oct; 17(3):1-9. PubMed ID: 10173306
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The E23K variant of KCNJ11 and the risk for severe sulfonylurea-induced hypoglycemia in patients with type 2 diabetes.
    Holstein A; Hahn M; Stumvoll M; Kovacs P
    Horm Metab Res; 2009 May; 41(5):387-90. PubMed ID: 19214942
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Practical considerations and guidelines for dosing sulfonylureas as monotherapy or combination therapy.
    Bell DS
    Clin Ther; 2004 Nov; 26(11):1714-27. PubMed ID: 15639686
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metformin: a new treatment option for non-insulin-dependent diabetes mellitus.
    Goo AK; Carson DS; Bjelajac A
    J Fam Pract; 1996 Jun; 42(6):612-8. PubMed ID: 8656173
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-acting sulfonylureas -- long-acting hypoglycaemia.
    Veitch PC; Clifton-Bligh RJ
    Med J Aust; 2004 Jan; 180(2):84-5. PubMed ID: 14723592
    [No Abstract]   [Full Text] [Related]  

  • 9. Efficacy of insulin and sulfonylurea combination therapy in type II diabetes. A meta-analysis of the randomized placebo-controlled trials.
    Johnson JL; Wolf SL; Kabadi UM
    Arch Intern Med; 1996 Feb; 156(3):259-64. PubMed ID: 8572835
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of sulfonylurea agents in older diabetic patients.
    Peters AL; Davidson MB
    Clin Geriatr Med; 1990 Nov; 6(4):903-21. PubMed ID: 2224754
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of glimepiride in the effective management of Type 2 diabetes.
    Davis SN
    J Diabetes Complications; 2004; 18(6):367-76. PubMed ID: 15531188
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of troglitazone on insulin action and cardiovascular risk factors in patients with non-insulin-dependent diabetes.
    Sironi AM; Vichi S; Gastaldelli A; Pecori N; Anichini R; Foot E; Seghieri G; Ferrannini E
    Clin Pharmacol Ther; 1997 Aug; 62(2):194-202. PubMed ID: 9284856
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sulfonylureas and mortality in diabetic patients after myocardial infarction.
    Brady PA; Al-Suwaidi J; Kopecky SL; Terzic A
    Circulation; 1998 Feb; 97(7):709-10. PubMed ID: 9495313
    [No Abstract]   [Full Text] [Related]  

  • 14. Insulin in the early management of diabetic complications.
    Miles JM
    J Assoc Physicians India; 2003 May; 51():501-5. PubMed ID: 12974435
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Possible risk of sulphonylureas in the treatment of non-insulin-dependent diabetes mellitus and coronary artery disease.
    Fasching P
    Diabetologia; 1998 Jun; 41(6):743-4. PubMed ID: 9662063
    [No Abstract]   [Full Text] [Related]  

  • 16. Pharmacodynamic effects of oral contraceptive steroids on biochemical markers for arterial thrombosis. Studies in non-diabetic women and in women with insulin-dependent diabetes mellitus.
    Petersen KR
    Dan Med Bull; 2002 Feb; 49(1):43-60. PubMed ID: 11894723
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incidence and risk factors for serious hypoglycemia in older persons using insulin or sulfonylureas.
    Shorr RI; Ray WA; Daugherty JR; Griffin MR
    Arch Intern Med; 1997 Aug 11-25; 157(15):1681-6. PubMed ID: 9250229
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Replacing SUs with incretin-based therapies for type 2 diabetes mellitus: challenges and feasibility.
    Knop FK; Holst JJ; Vilsbøll T
    IDrugs; 2008 Jul; 11(7):497-501. PubMed ID: 18600596
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sulphonylureas in the treatment of non-insulin-dependent diabetes.
    Ferner RE; Alberti KG
    Q J Med; 1989 Nov; 73(271):987-95. PubMed ID: 2695959
    [No Abstract]   [Full Text] [Related]  

  • 20. Sulfonylureas improve insulin binding and insulin action in non-insulin-dependent diabetes mellitus.
    Beck-Nielsen H; Hjøllund E; Pedersen O; Richelsen B; Sørensen NS
    Diabetes Care; 1984; 7 Suppl 1():100-5. PubMed ID: 6428842
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.